可吸入干细胞外泌体雾化疗法促进心肌梗死后心脏修复
研究报道一种经雾化吸入递送干细胞外泌体的无创可重复疗法(SCENT),在小鼠心肌梗死模型中改善左室功能、减少纤维化并促进心肌细胞增殖,机制涉及内皮细胞Cd36下调;在猪心肌梗死模型中磁共振显示射血分数与缩短分数提高,并减小梗死面积、增厚心室壁。
要点
- SCENT经雾化吸入递送外泌体,为无创、可重复的给药方式
- 小鼠MI模型中改善左室功能、减少纤维化、促进心肌细胞增殖
- 机制与内皮细胞Cd36下调及心肌葡萄糖利用和ATP生成增加相关
核心结论
- 在小鼠和猪心肌梗死模型中,SCENT治疗被证明对急性MI损伤具有可行性、疗效和总体安全性,为临床研究奠定基础。
- 内皮细胞条件性敲除CD36的小鼠模型首次在体内证明EC-CD36敲除可减轻心脏损伤,提示新的潜在治疗靶点。
研究设计与样本
- 研究对干细胞来源外泌体进行粒径分布和表面标志物表征。
- C57BL/6小鼠MI模型经雾化器连续7天接受外泌体吸入治疗,并行超声心动图、组织学及全心脏单细胞RNA测序。
- 在猪MI模型中借助三维心脏磁共振评估SCENT的可行性、疗效和总体安全性。
主要发现
- 离体IVIS成像和荧光显微镜检测到SCENT后外泌体募集至缺血心脏。
- 小鼠MI模型中SCENT改善左心室功能、减少纤维化组织并促进心肌细胞增殖。
- 小鼠心脏单细胞RNA测序显示SCENT后内皮细胞Cd36下调。
- EC-Cd36fl/-条件敲除小鼠中抑制内皮细胞脂肪酸转运体CD36导致心脏葡萄糖利用代偿性增加、ATP生成增高,增强心肌收缩力。
- 猪MI模型第28天磁共振显示SCENT组较对照组射血分数提高(Δ=11.66±5.12%)、缩短分数提高(Δ=5.72±2.29%),并伴梗死面积减小和心室壁增厚。
临床怎么用
- SCENT为心肌梗死后心脏修复提供一种无创、可重复的雾化吸入外泌体治疗思路,但尚需临床研究验证。
- 内皮细胞CD36及其下游葡萄糖利用/ATP生成通路可作为后续药物或基因干预的潜在靶点研究方向。
局限性
- 研究为小鼠和猪模型中的临床前实验,尚未在人体中验证疗效与安全性。
- 摘要未报告外泌体表征的具体数值、样本量及统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell-derived exosome nebulization therapy (SCENT). METHODS: Stem cell-derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging. RESULTS: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of Cd36 in endothelial cells (ECs). In an EC-Cd36fl/- conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall. CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-Cd36fl/- mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.
引用
- Li, Sun, Zhu, et al. Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction. Circulation. 2024. PMID: 39186525. doi:10.1161/CIRCULATIONAHA.123.065005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。